Tokyo, Japan and Cambridge, UK, 29 March 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, today announces the publication of its inaugural ESG Report for 2022 (“the Report”). The Report describes the Company’s efforts to prioritize, address and measure its progress on a range of Environmental, Social and Governance (ESG) objectives determined to make a positive impact on its employees, the wider community in which it operates, and the environment. 

The Report has been prepared by the Company’s new ESG Committee which was established in 2022 with the support of our Board of Directors. The ESG Committee is chaired by Ms. Miwa Seki, an independent external director of the Company, who is also a founding partner of an ESG-oriented investment fund in Japan. Since its establishment, the Committee has worked to assess the Company’s current ESG policies, performances and practices and identify potential priority areas of focus.

The Company believes that enhancing disclosure of its ESG initiatives is a vital component for its  long-term growth and success. With this overarching objective, the Company will continue its efforts and focus on driving forward its ESG initiatives in 2023 and beyond so that environmental, social, and governance topics become foundations of  Sosei Heptares’ culture, values and business operations.

The full report can be found here.

-ENDS-